Antibody drug conjugates market to be worth $15bn by 2030
Antibody drug conjugates are presently recognised as a potent class of targeted anticancer therapies which will result in growth in the market.
List view / Grid view
Antibody drug conjugates are presently recognised as a potent class of targeted anticancer therapies which will result in growth in the market.
A US district court has invalidated Amgen's patent claims for antibodies targeting PCSK9.
A statement from 11 health union leaders highlights the possibility of severe drug shortages if the UK leaves the EU without a deal.
Fast Track designation has been granted to Farxiga to prevent heart and kidney failure in patients with chronic kidney disease.
The government in China has stated that small quantities of generic medicines that are legal in foreign countries will no longer be classed as “fake drugs”.
The licence extension submission for Invokana and Vokanamet has been accepted by the EMA.
A large number of drug manufacturers are failing to complete the FDA's Accelerated Approval Program, meaning not all available drugs are fully approved, finds a study.
Five pharma companies have filed a complaint in Canadian court over new rules intended to lower the price of drugs in the country.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this third piece, we discuss the future of the cannabinoid industry and how it will grow within the realm of pharmaceuticals.
A recent report has predicted that the cervical cancer vaccine market will increase to $6bn by the end of the forecast period.
Ningbo Huize Commodity Co has been sent a warning letter for cGMP violations, including data integrity issues.
A study has found that between 2014 and 2016, the EMA and FDA had very little divergence in their marketing authorisation decisions.
Drug companies are still raising prices for brand-name prescription medicines but not as often or by as much as they used to.
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).